Zurcher Kantonalbank Zurich Cantonalbank Has $250,000 Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Zurcher Kantonalbank Zurich Cantonalbank decreased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 19.9% in the fourth quarter, HoldingsChannel reports. The firm owned 148,036 shares of the company’s stock after selling 36,725 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Ginkgo Bioworks were worth $250,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its holdings in shares of Ginkgo Bioworks by 9.0% in the 4th quarter. ARK Investment Management LLC now owns 198,606,619 shares of the company’s stock valued at $335,645,000 after purchasing an additional 16,414,434 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Ginkgo Bioworks by 15.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 58,746,160 shares of the company’s stock worth $106,331,000 after buying an additional 7,958,613 shares in the last quarter. Welch & Forbes LLC acquired a new stake in shares of Ginkgo Bioworks during the 3rd quarter valued at $12,670,000. Vanguard Group Inc. grew its holdings in shares of Ginkgo Bioworks by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 132,316,999 shares of the company’s stock valued at $239,494,000 after acquiring an additional 4,016,221 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Ginkgo Bioworks by 26.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 7,418,397 shares of the company’s stock worth $13,427,000 after acquiring an additional 1,554,080 shares during the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DNA. TD Cowen reduced their price objective on Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. The Goldman Sachs Group reduced their price objective on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a research note on Monday, January 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $2.20.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Mark E. Dmytruk sold 47,806 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the transaction, the insider now owns 925,400 shares of the company’s stock, valued at $777,336. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Mark E. Dmytruk sold 47,806 shares of Ginkgo Bioworks stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total transaction of $40,157.04. Following the sale, the insider now directly owns 925,400 shares of the company’s stock, valued at $777,336. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Mark E. Dmytruk sold 51,169 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total value of $53,727.45. Following the transaction, the insider now owns 865,079 shares in the company, valued at $908,332.95. The disclosure for this sale can be found here. Insiders own 15.05% of the company’s stock.

Ginkgo Bioworks Stock Up 3.4 %

Shares of NYSE:DNA opened at $0.99 on Tuesday. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -2.10 and a beta of 1.42. The business has a 50 day moving average price of $1.08 and a 200 day moving average price of $1.31. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $0.74 and a twelve month high of $2.55.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The business had revenue of $34.76 million during the quarter, compared to the consensus estimate of $40.37 million. During the same period in the prior year, the company posted ($0.04) earnings per share. The firm’s revenue was down 64.6% compared to the same quarter last year. Analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.32 EPS for the current year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.